Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial

Abstract Background Myelofibrosis (MF) is a clonal haematopoietic disease, with median overall survival for patients with primary MF only 6.5 years. The most frequent gene mutation found in patients is JAK2 V617F, causing constitutive activation of the kinase and activation of downstream signalling....

Full description

Bibliographic Details
Main Authors: Graham McIlroy, Charlotte Gaskell, Aimee Jackson, Emily Yafai, Rachel Tasker, Catherine Thomas, Sonia Fox, Rebecca Boucher, Fitsum Ghebretinsea, Claire Harrison, Adam J. Mead, Mary Frances McMullin
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Cancer
Subjects:
Myelofibrosis
Phase II
Clinical trial
Fedratinib
Ropeginterferon alfa-2b
JAK2 inhibition
Online Access:https://doi.org/10.1186/s12885-024-13383-3

Internet

https://doi.org/10.1186/s12885-024-13383-3

Similar Items